Protein tyrosine phosphatase non-receptor type 9 (PTPN9)

Protein tyrosine phosphatase non-receptor type 9 (PTPN9), also known as PTP-MEG2, is a non-receptor protein tyrosine phosphatase that plays a vital role in regulating various cellular processes including vesicle fusion, growth factor signaling, and metabolic pathways [1, 2]. It is uniquely characterized by an N-terminal Sec14-like domain that mediates its binding to phosphoinositides, allowing it to localize to secretory vesicles and regulate their fusion with the plasma membrane [1]. PTPN9 acts as a negative regulator of several key signaling molecules, such as the insulin receptor, epidermal growth factor receptor (EGFR), and STAT3, thereby influencing cell growth and insulin sensitivity [3, 4]. In the context of human disease, PTPN9 is frequently found to be downregulated in various cancers, including breast and hepatocellular carcinoma, where it functions as a tumor suppressor by inhibiting oncogenic signaling [3, 5]. Conversely, its role in dephosphorylating the insulin receptor suggests that its inhibition could potentially enhance insulin sensitivity in metabolic disorders like type 2 diabetes [4]. Therapeutic strategies targeting PTPN9 include the development of small-molecule inhibitors for metabolic applications and the use of RNA interference (mRNA targeting) to study its complex roles in cellular signaling [3, 6]. However, achieving high selectivity remains a significant challenge due to the structural similarity of the catalytic domains among the protein tyrosine phosphatase family members [1, 3].

Other names

PTP-MEG2MEG2Protein-tyrosine phosphatase MEG2

Small molecule inhibition of the catalytic phosphatase domain or antisense-mediated degradation of mRNA to reduce protein expression.